Bayer has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Medrad Centargo CT Injection System.
The system is a multipatient injector that integrates with Bayer’s portfolio of products, especially in high-volume CT suites. It is designed to minimize preparation time to under two minutes, streamlines data entry, and features a piston-based technology that allows for features such as dual flow to deliver contrast and saline at the same time, the company said.
By integrating with Bayer’s portfolio of imaging and workflow solutions, the company added that healthcare providers can optimize contrast usage and enable connectivity to the modality worklist and scanner.
Sunnybrook Health Sciences Centre in Toronto, Canada was the first hospital in North America to install and integrate Bayer’s Medrad Centargo CT Injection System in both acute care and outpatient settings.
![Images show the pectoralis muscles of a healthy male individual who never smoked (age, 66 years; height, 178 cm; body mass index [BMI, calculated as weight in kilograms divided by height in meters squared], 28.4; number of cigarette pack-years, 0; forced expiratory volume in 1 second [FEV1], 97.6% predicted; FEV1: forced vital capacity [FVC] ratio, 0.71; pectoralis muscle area [PMA], 59.4 cm2; pectoralis muscle volume [PMV], 764 cm3) and a male individual with a smoking history and chronic obstructive pulmonary disorder (COPD) (age, 66 years; height, 178 cm; BMI, 27.5; number of cigarette pack-years, 43.2, FEV1, 48% predicted; FEV1:FVC, 0.56; PMA, 35 cm2; PMV, 480.8 cm3) from the Canadian Cohort Obstructive Lung Disease (i.e., CanCOLD) study. The CT image is shown in the axial plane. The PMV is automatically extracted using the developed deep learning model and overlayed onto the lungs for visual clarity.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/03/genkin.25LqljVF0y.jpg?auto=format%2Ccompress&crop=focalpoint&dpr=2&fit=crop&h=167&q=70&w=250)
